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Stemness Evaluation of Mesenchymal Stem Cells from Placentas 
According to Developmental Stage: Comparison to Those from 
Adult Bone Marrow
This study was done to evaluate the stemness of human mesenchymal stem cells (hMSCs) 
derived from placenta according to the development stage and to compare the results to 
those from adult bone marrow (BM). Based on the source of hMSCs, three groups were 
defined: group I included term placentas, group II included first-trimester placentas, and 
group III included adult BM samples. The stemness was evaluated by the proliferation 
capacity, immunophenotypic expression, mesoderm differentiation, expression of 
pluripotency markers including  telomerase activity. The cumulative population doubling, 
indicating the proliferation capacity, was significantly higher in group II (P<0.001, 31.7±5.8 
vs. 15.7±6.2 with group I, 9.2±4.9 with group III). The pattern of immunophenotypic 
expression and mesoderm differentiation into adipocytes and osteocytes were similar in all 
three groups. The expression of pluripotency markers including ALP, SSEA-4, TRA-1-60, 
TRA-1-81, Oct-4, and telomerase were strongly positive in group II, but very faint positive 
in the other groups. In conclusions, hMSCs from placentas have different characteristics 
according to their developmental stage and express mesenchymal stemness potentials 
similar to those from adult human BMs.
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INTRODUCTION
Human mesenchymal stem cells (hMSCs) are multipotent adult 
stem cells that can differentiate into a variety of cell types, in-
cluding osteoblasts, chondrocytes, myocytes, adipocytes, neu-
ronal cells, and beta-pancreatic islets cells. hMSCs have been 
identified in many human adult organs (e.g, bone marrow, pe-
ripheral blood, cornea/retina, brain, skeletal muscle, dental pulp, 
liver, and adipose tissues) as well as in the fetus, including the 
liver, bone marrow, kidney, umbilical vein endothelial/suben-
dothelial layer, and in the blood of preterm fetuses (1-4). Human 
bone marrow (hBM) has been the main source of hMSCs, some-
times referred to as bone marrow stromal cells because of their 
characteristics and capacity to transform into mesodermal tis-
sues, such as adipocytes, osteoblasts, and chondrocytes. How-
ever, the use of hBM as the source for hMSCs is limited by the 
invasive collection procedure required as well as a decrease in 
cell number, proliferation, and differentiation capacity in vitro 
with the age of the culture (5). This has led many researchers to 
investigate alternate sources of hMSCs that can be used in the 
clinical setting. 
  Human umbilical cord blood (hUCB), which is an increasing-
ly accepted source for hematopoietic stem cell transplantation 
in children and adults (6), has been considered as an alternative 
source of hMSCs. However, whether hUCBs is an acceptable 
source of hMSCs continues to be investigated. Some studies have 
reported that hMSCs were not present in the hUCB from term 
deliveries and were identified only in fetal blood (7). Recently, 
the presence of hMSCs in the human placenta (hPC) has been 
confirmed and reported to be a valuable and practical source 
for tissue engineering (8-11). Studies that compared the char-
acteristics of the hMSCs from hPC with those from hBM have 
reported different features in the hMSCs collected from the fetal 
side compared to those collected from the maternal side of the Sung HJ, et al.  •  Stemness of Mesenchymal Stem Cells from Placentas
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hPC (10, 12). Moreover, Guillot et al. (13) reported that human 
first-trimester fetal hMSCs express pluripotency markers and 
grow faster than adult hMSCs. In addition, a study showing dif-
ferences between the hMSCs of fetal tissues and adult tissues 
was recently reported (13, 14). Furthermore, Mikkola et al. (15) 
showed that the preterm hPC from the first-trimester, not the 
term hPC, would be preferred for the study of hematopoietic 
stem cell development. These findings suggest the presence of 
some differences between the hMSCs from the preterm hPC 
during the first-trimester compared to those from the term hPC. 
However, there is no prior study comparing the features of mes-
enchymal and pluripotent stemness of hMSCs derived from 
first trimester preterm hPCs in embryonic to early fetal develop-
mental stage, with term hPCs during the late fetal developmen-
tal stage and human adult bone marrow (hBM). Therefore, this 
study was designed to evaluate the proliferation capacity, phe-
notypic expression, mesoderm differentiation, expression of 
pluripotency stem cell markers including telomerase activity, 
and karyotype stability of hMSCs derived from term hPCs and 
compare the results with preterm hPCs from the first trimester 
and from adult hBM. 
 
MATERIALS AND METHODS
Derivation of the cells from placenta and bone marrow
We obtained five first-trimester hPCs at 8-12 weeks gestational 
age from women that had undergone therapeutic abortion due 
to known maternal disease that is aggravated by pregnancy and 
five term hPCs at 38-40 weeks of gestational age from healthy 
pregnant women, after the acquisition of written informed con-
sent. Loose chorion, amniotic sac, and decidua were removed 
from the placenta. Human chorionic plate (hCP) membranes 
were surgically separated from the placenta by the specialist of 
Obstetrics, incubated in 0.25% trypsin-EDTA (ethylene amine 
tetra acetic acid; GIBCO-Invitrogen, Carlsbad, CA, USA) at 37°C 
for 30 min, and then washed with PBS. Thereafter, the cells were 
isolated from the hCP by digestion with 0.05% collagenase type 
1 (Sigma-Aldrich, St. Louis, MO, USA) at 37°C for 30 min and 
washed three times with PBS. Adult hBM was obtained from 
five healthy males that voluntarily donated their hBM for alloge-
neic hematopoietic stem cell transplantation for which they gave 
written informed consents. Mononuclear cells (MNCs) were 
isolated from heparinized hBM aspirates (diluted with equal 
volume of PBS) by standard density (1.077 g/mL) centrifugation 
using Ficoll (Sigma-Aldrich, St.Louis, MO, USA). The MNCs at 
the interface were recovered, washed, and resuspended in the 
medium composed of Dulbecco’s Modified Eagle’s Medium 
(DMEM) with low glucose, 10% fetal bovine serum (FBS), and 
1% antibiotic-antimycotic stock solution (all from GIBCO-Invit-
rogen). This study was conducted prospectively, with the approv-
al of the Institutional Review Board for human research in Korea 
University Medical Center (IRB approval number: AN09085-
001) and all patients provided written informed consent.
 
Microbiology evaluation
All of the collected tissues were microbiologically evaluated be-
fore culture, because hMSCS infected by pathogens should not 
be clinically applied. The samples were tested for bacteria, Chla-
mydia spp., Cytomegalovirus, Herpes simplex virus types 1 and 
2, Mycoplasma spp., and Ureaplasma urealyticum. In addition, 
Mycoplasma spp. detection was assessed by the polymerase 
chain reaction (PCR) with branded products. The PCR Myco-
plasma detection set (TaKaRa
®, Shiga, Japan ) is a primer set 
designed to detect the presence of Mycoplasma (M. fermentans, 
M. hyorhinis, M. arginini, M. orale, M. salivarium, M. hominis, 
M. pulmonis, M. arthritidis, M. neurolyticum, M. hyopneumoni-
ae, M. capricolum) and one species of Ureaplasma (U. urealyti-
cum). 
Karyotype evaluation
Evaluation of chromosome stability was performed at every fifth 
passage. The hMSCs were incubated with 0.1 μg/mL colcemid 
for three to four hours, trypsinized, and then incubated in 0.075 
M KCL for 20 min at 37°C. After fixation with 3:1 methanol/ace-
tic acid, the karyotypes of the hMSCs were determined at the 
300-band level of resolution. The tissues showing abnormal 
karyotypes would have been excluded from this study, but no 
abnormal karyotypes were detected. 
hMSCs Culture of the cells derived from placenta and 
bone marrow
Isolated normal cells were placed into 175-cm
2 flasks and long 
term cultures established using DMEM (GIBCO-Invitrogen) 
supplemented with 10% fetal bovine serum (FBS; HyClone Lab-
oratories Inc, Logan, UT, USA), 100 U/mL penicillin, and 100 μg/ 
mL streptomycin at 37°C, with 5% CO2 and 95% humidity. The 
medium was changed after 48 hr and every 3-4 days thereafter. 
When the cultures (the primary passage) reached approximate-
ly 90% confluence, hMSCs were recovered by digestion with 
0.05% trypsin/0.53 mM EDTA solution (GIBCO-Invitrogen) and 
replated in passage culture at a density of about 5,000 cells per 
cm
2. Once confluent, the harvested (passage 1) cells were simi-
larly prepared and seeded to obtain passage two (P2) cells and so 
on. Based on the source of the hMSCs, three groups were estab-
lished: group I included samples from term placentas, group II 
from preterm placentas, and group III from adult bone marrow. 
Proliferation capacity and morphological characteristics 
To examine the proliferation capacity of the hMSCs in vitro, the 
cumulative population doubling (PD) was measured over 50 
days. The hMSCs were plated in triplicate at a concentration of 
10
4 cells per cm
2 in 10-cm
2 dishes and successively subcultured Sung HJ, et al.  •  Stemness of Mesenchymal Stem Cells from Placentas
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at the same density. The cells were counted using a hemocytom-
eter and trypsin blue was used to exclude dead cells; this pro-
cess was serially repeated three times over 50 days. The cumu-
lative cell doubling of the cell populations was plotted against 
time in the culture to determine the growth kinetics of hMSC 
expansion. The number of population doubling was determined 
by counting the number of adherent cells at the start and end of 
each passage. The population doubling was calculated at every 
passage according to the equation: log2 (the number of harvest-
ed cells/the number of seeded cells). The finite population dou-
bling was determined by the cumulative addition of the total 
numbers generated from each passage until the cells stopped 
dividing.
  To study the morphological characteristics of the cells, the cell 
culture flasks were examined at all medium re-feeding intervals 
(every 4 days), to detect any abnormalities in cell morphology 
and/or medium. When any variation was observed, the chang-
es were recorded in the culture files.
Immunophenotypic expression
The culture expanded cells were labeled with the following an-
ti-human antibodies, used for the characterization of hMSCs, at 
the fifth passage: CD29-PE (phycoerythrin), CD31-FITC (fluo-
rescein isothiocyanate), CD34-FITC, CD44-FITC, CD45-FITC, 
CD90-FITC, CD105-FITC, HLA-ABC-PE and HLA-DR-FITC (all 
Becton Dickinson [BD], San Jose, CA, USA). After exposure to 
labeled antibodies, the cells were washed and resuspended in 
ice cold PBS . More than 50,000 labeled cells were acquired and 
analyzed using FACS-Vantage-SE flow cytometry running Cell-
Quest software (BD). Negative control samples were stained with 
isotype-matched irrelevant monoclonal antibodies. The data 
were analyzed with Cellquest software. 
Mesoderm differentiation
This study was performed on the hMSCs at the fifth passage. 
Osteogenic differentiation was induced using hMSCs medium 
with osteogenic supplements. For the in vitro osteogenic assays, 
the hMSCs were plated at densities of 3.1×10
3 cells/cm
2 in 0.2 
mL/cm
2 of medium on tissue culture dishes. The following day 
(day 0), the culture dish was replaced with osteogenic medium 
(100 nM dexamethasone, 10 mM β-glycerophosphate, and 50 M 
L-ascorbic acid 2-phosphate), which was changed twice a week 
until day 21. The hMSC medium served as the control. After 21 
days, Von Kossa and alkaline phosphate staining were used to 
demonstrate the presence of calcium phosphate. 
  To induce adipogenic differentiation, the cells were plated at 
1 to 2×10
4 cells/cm
2 and cultured in DMEM (low glucose) plus 
10% FBS and fed. Every 2-3 days, the medium was replaced un-
til the cultures reached confluence (5-10 days) in the 35-mm 
diameter plastic dishes (BD). At 100% confluence, the cultures 
were treated with an adipogenic-induction medium composed 
of DMEM (low glucose) plus 10% FBS containing 0.5 mM iso-
butyl-methylxanthine (IBMX), 1 μM dexamethasone, 10 μg/mL 
insulin and 0.2 mM indomethacin for 3 days, followed by the 
maintenance medium composed of DMEM (high glucose) con-
taining 10 μg/mL insulin for 3 days. Adipogenic differentiation 
was assessed using Oil Red-O stain as an indicator of intracel-
lular lipid accumulation.
 
Detection of pluripotency markers 
Immunofluorescence histochemistry examinations with pluri-
potency markers expressed in human embryonic stem cells 
(hESCs), including SSEA-1, SSEA-3, SSEA-4 (Hybridoma Bank, 
University of Iowa, IA, USA), tumor rejection antigen (TRA)-1-
60, TRA-1-81 (Chemicon, Temecula, CA, USA) and OCT-4 were 
performed on the hMSCs at the fifth passage. The hMSCs were 
washed twice with PBS and fixed with 100% ethanol for 2 min. 
Cells were then washed with 1% BSA(Bovine serum albumin, 
Sigma)/PBS and incubated for 1 hr at room temperature with 
100 mL of undiluted antibody against SSEA-1, SSEA-3, SSEA-4, 
TRA-1-60, TRA-1-81 and OCT-4. The cells were washed twice 
with 1% BSA/PBS and incubated in the dark with a 1:500 dilu-
tion of goat anti-mouse PE-conjugate for another hour. Simul-
taneously, the nuclei of the cells were stained with a 1:1,000 di-
lution DAPI (4´,6-diamidino-2-phenylindole) solution. The cells 
were washed twice and sufficient 1% BSA/PBS was added to 
cover the cells. UV filtered images were then taken under the 
IX70 Olympus microscope at 100×magnification.
  To compare the undifferentiated state of the hMSCs, we per-
formed RT-PCR for Oct-4 and telomerase, which is highly ex-
pressed in undifferentiated stem cells. Oct-4 is a marker for the 
undifferentiated status of stem cells and is expressed in plurip-
otent cell populations, such as early embryonic cells. Its expres-
sion can influence the status of pluripotency. For reverse tran-
scriptase (RT), first strand complementary DNA was synthesized 
from 2 μg of total RNA and the polymerase chain reaction (PCR) 
was performed using 0.2 μg of 1:10 diluted cDNA on an Bioer XP 
cycler (Bioer Technology Co. LTD. Hangzhou, Zhejiang, China) 
in a 50 μL reaction mixture that contained 10 pM of forward and 
reverse primers (sequences are given in Table 1), 10×PCR buffer, 
dNTP mixture 10 mM, and 2.5 U Taq polymerase (GENENMED, 
Seoul, Korea). Reaction PCR products were separated by gel elec-
Table 1. RT-PCR oligonucleotide primer sequences 
Gene name                                  Primer
Oct-4 Forward : gga aag gct tcc ccc tca ggg aaa gg, 
Reverse : aag aac atg tgt aag ctg cgg ccc
hTR  Forward : tct aac cct aac tga gaa ggg cgt ag
Reverse : gtt tgc tct aga atg aac ggt gga ag
hTERT Forward : cgg aag agt gtc tgg agc aa
Reverse : gga tga agc gga gtc tgg a
β-actin Forward : cct tcc tgg gca tgg agt ggt g
Reverse : gga gca atg atc ttg atc ttcSung HJ, et al.  •  Stemness of Mesenchymal Stem Cells from Placentas
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trophoresis using a 1.5% agarose gel. Bands were visualized by 
UV illumination of ethidium-bromide–stained gels. Band inten-
sity was normalized to corresponding β-actin values. Telomer-
ase activity is high in hESCs, but rarely detectable in hMSCs from 
adult tissues. We have conducted telomeric repeat amplication 
protocol (TRAP) to evaluate telomerase activity of MSCs derived 
from human placenta and adult BM. 
Statistical analysis
The results were confirmed by two additional investigators. All 
quantitative data are presented as the mean±SEM and statisti-
cal significance was determined using the one-way ANOVA. 
Results were considered significant when the P value was less 
than 0.05. 
RESULTS
Proliferation capacity and morphological characteristics 
The comparative growth kinetics of the hMSCs involved in this 
study over 50 days at a cell density of 10
4 cells per cm
2 showed 
that the hMSCs of group II had a statistically higher growth po-
tential of cumulative PDs, achieving 31.7±5.8, whereas those of 
the groups I and II were 15.7±6.2 and 9.2±4.9, respectively (P< 
0.001); with cumulative PDs, progressively increasing in group 
II, but slowing in groups I and III. The hMSCs of group II from 
the first-trimester preterm hPCs underwent up to 20 passages 
and displayed no visible changes with regard to their morphol-
ogy by light microscopy, forward and side scatter properties on 
flow cytometry, or growth patterns. The numbers of possible 
passages for subcultures maintaining the initial morphology of 
groups I and II were 14.2±3.3 and 11.8±4.1, respectively, which 
were both fewer than the 20 passages (Figs. 1, 2).
 
Immunophenotypic expression
All mesenchymal immunophenotypic expression patterns of 
the cells involved in this study were the same. Flow cytometry 
examination revealed that all of the cells were negative for CD34 
(gp105-120) and CD45 (leukocyte common antigen), indicating 
that these cells were not of hematopoietic origin. The cells were 
also negative for the matrix receptor CD31 (PECAM-1) and HLA-
Fig. 1. Cells from the human placentas and human bone marrow. (A) Cells from the human term placenta. (B) Cells from the first –trimester placenta. (C) Mesenchymal stem 
cells(MSC) from the human bone marrow. The placenta derived cells show a fibroblastoid, spindle-shaped morphology at passage 3 on day 5. The growth pattern of the cells 
from the term and first-trimester placenta was same as the bone marrow derived mesenchymal stem cells. Phase contrast: magnification ×100 for all figures.
A B C
Fig. 2. Proliferation Capacity. (A) Cumulative population doublings of Mesenchymal stem cells from first-trimester human placenta (hPC), term human placenta (hPC) and Bone 
marrow. (B) The possible passages for subcultures with the maintenance of initial morpholology and growth pattern of three population of mesenchymal stem cells. 
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DR. The cells were positive for integrin CD29 (β1-integrin), ma-
trix receptor CD44 (hyaluronate receptor), CD90 (Thy-1), CD105 
(endoglin), and HLA-A, B, C (Fig. 3).
Mesoderm differentiation
Cells derived from the first-trimester and term placentas were 
cultured in osteogenic media and started to aggregate in 7 days, 
and then made multiple colony–like nodules in 14 days (Fig. 4). 
Von Kossa and alkaline phosphatase staining showed osteogen-
ic differentiation, similar to the hBM cells. Adipogenic differen-
tiation was evaluated by adipogenic induction and maintenance 
media cultures. Morphologic changes of the cells from the first-
trimester placenta and term placentas, as well as the cells from 
the hBM, included the formation of neutral lipid vacuoles, which 
were noted at 3 weeks and visualized by the staining with Oil-
Red-O (Fig. 5).
Detection of pluripotency markers 
ALP staining was strongly positive in the group II hMSCs from 
first-trimester hPCs. However, it was weaker and more blurred 
for the hMSCs in group I and III. The expression of Oct-4 and 
telomerase activity were clearly identified in group I , but not in 
group II hMSCs from the hPCs and group III hMSCs (Figs. 6, 7). 
All of the immunocytochemical stains for SSEA-4, TRA-1-60, 
and TRA-1-81 on hESCs were strongly positive in group II hM-
SCs from preterm hPC but faint in the hMSCs from group I and 
II (Fig. 8).
Microbiology evaluation
Positive findings were observed in 4 samples from human pla-
centas, but not in the human bone marrow samples. The tis-
sues showing positive reaction from the Mycoplasma detection 
set (TaKaRa
®) were excluded for this study (The data were not 
shown).
DISCUSSION
The purpose of this study was to evaluate and compare the mes-
enchymal and pluripotential stemness features of hMSCs de-
rived from first trimester hPCs during the embryonic to early 
stage of development, term hPCs during the late fetal stage of 
development and adult human bone marrow (hBM). The results 
showed better proliferation potential with the expression of plu-
ripotency markers in the hMSCs of first-trimester placentas dur-
ing the embryonic to early fetal stage of development compared 
to the late fetal and adult stages. In addition, late fetal and adult 
hMSCs did not strongly express pluripotency markers such as 
Oct-4, SSEA-3, SSEA-4, Tra-1-60, and Tra-1-81, which suggests 
remarkable growth capacity. These findings are consistent with 
those reported by Guillot et al. on first-trimester fetal blood, liver, 
and bone marrow hMSCs. However, Guillot et al. (13) did not 
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Fig. 3. Immunophenotype of MSCs. BM-derived MSCs (BM-MSC), first-trimester 
placenta derived cells and term placenta derived cells were labeled with antibodies 
against the indicated antigens, and analyzed by flow cytometry. Representative histo-
grams are demonstrated. All types of cells showed the same immunophenotypic cha-
racteristics: positive expression of CD29, CD44, CD90, CD105 and HLA-ABC as sur-
face epitopes, and negative expression of CD31, CD34, CD45 and HLA-DR.Sung HJ, et al.  •  Stemness of Mesenchymal Stem Cells from Placentas
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study the growth capacity or expression degree of pluripotency 
markers in first-trimester hPCs. Therefore, this study is the first 
report showing that hMSCs from first-trimester preterm hPCs 
express pluripotency markers. In addition, the population dou-
bling at this stage was similar to the results of the first-trimester 
fetal liver, blood, and bone marrow reported by Guillot et al. (13). 
In this study, telomerase expression of the hMSCs from the pre-
Fig. 4. Osteogenic differentiation from placenta derived cells. For osteogenic differentiation, first-trimester placenta derived cells were cultured for up to 3 weeks in osteogenic 
medium (OM). (A) First-trimester placenta derived cells aggregate in 7 days and formed nodules at 14-21 days. (B) First-trimester placenta derived cells exhibit alkaline pho-
sphatase activity at 2 weeks. (C) Von Kossa staining-positive aggregates or nodules are found after 3 weeks, which shows significant calcium deposition in osteogenic media.
OM D4
OM D14
OM D14
OM D14 D21
D7
D21
D21
A C
B
A B C D
E F G H
I J K L
Fig. 5. Adipogenic differentiation from placenta derived cells. Adipogenic differentiation was evaluated by culturing placenta-derived cells in adipogenic induction and 
maintenance medium for 3 weeks and evidenced by the formation of lipid vacuoles using Oil-Red-O staining and hematoxylin counterstaining. The first-trimester placenta-
derived cells form lipid vacuoles at 21 day (A-F). The term placenta-derived cells formed lipid vacuoles at 21 day as well (G-L). A, B, G, H: unstained. Original magnification: A, C, 
G, I, ×40; B, D, H, J ×100; E, K ×200; F, L, ×400.
term placentas of the embryo and early fetal stage was exam-
ined by the RT-PCR method. Telomerase expression in hMSCs 
is not expected due to the low telomerase activity at this stage  
of development (16). Nonetheless, telomerase expression was 
found in the hMSCs of the embryo and early fetal developmen-
tal stage in the preterm hPCs, but not during the late fetal and 
adult stages of development. This result suggests a higher telom-Sung HJ, et al.  •  Stemness of Mesenchymal Stem Cells from Placentas
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erase activity in the hMSCs from the preterm hPCs than from 
the term hPCs and adult hBM. High telomerase activity in the 
hMSCs from the first-trimester preterm hPCs might be related 
to the predominant proliferation potential and possibly with 
pluripotency marker expression. 
  There have been studies showing the same phenotypic ex-
pression between hMSCs originating from fetal tissue and those 
BM MSC
OCt-4
β-actin
Term hPC
First trimester hPC
Fig. 6. The expression of Oct4 in first trimester, term placenta and BM derived Mesen-
chymal stem cells (MSCs). The expression of Oct-4 is strong in first-trimester hPC MSCs 
and weak in term placenta hPC and adult BM derived MSCs as shown by RT-PCR.
Fig. 7. The detection of telomerase activity by the TRAP assay shows the specific signal 
intensity of telomerase-specific 6-base repeat ladder. First lane shows the expression 
of telomerase activity in positive control 293T cell; 1st -trimester hPC lane shows the 
expression of telomerase activity; term hPC and BM MSC lane show the negative 
telomerase activity.
293T 1st trime- 
ster hPC
Term 
hPC
BM template 
control
Marker
SSEA-4
DAPI
SSEA-3
DAPI
SSEA-1
DAPI
Tra-1-81
DAPI
Tra-1-61
DAPI
OCT-4
DAPI
1st-trimester 
hPC (group II)
Term hPC 
(group I)
BM 
(group III)
Fig. 8. The detection of pluripotency marker. All of the immunocytochemical stains for 
SSEA-4, TRA-1-60, and TRA-1-81 on hESCs are strongly positive in group II from first- 
trimester hPC but very faint in group I (term hPC derived) and group III (BM derived) 
hMSCs. All magnification: ×40.Sung HJ, et al.  •  Stemness of Mesenchymal Stem Cells from Placentas
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from adult tissue (4, 9, 10, 17). This study also showed the same 
pattern of immunophenotypic expression in the hPCs, regard-
less of gestational age, and also in the adult hBM. The pattern 
and potential of mesoderm differentiation of the hMSCs to adi-
pocytes and osteocytes from the first-trimester preterm hPCs 
show  ed no significant differences compared to the hMSCs de-
rived from term hPCs during the late fetal stage of development 
and adult human bone marrow (hBM). This finding is some-
what different from those of other studies that found a higher 
potential for differentiation among fetal hMSCs compared to 
adult hMSCs (15, 18). Lee et al. (18) reported that rhesus monkey 
MSCs derived from early third-trimester BM showed greater 
proliferation and differentiation potential than those from adult 
BM. Guillot et al. (13) also suggested that the osteogenic effi-
ciency of the fetal hMSCs was greater than that of adult hMSCs. 
The adipogenic and osteogenic differentiation was evaluated in 
this study, but not chondrogenic differentiation; this is because it 
was well known that typical mesodermal differentiation can be 
induced to form adipocytes and osteocytes (5, 9, 19, 20). Further 
studies to clarify the differentiation potentials of hMSCs origi-
nating from fetal tissues and adult tissues are needed. 
  To apply the products from hMSCs to human treatment, chro-
mosomal safety must be confirmed. It is very difficult to find 
studies that have examined the chromosomes of the hMSCs. 
Human stem cells that can be used for long term passage, espe-
cially hESCs, have significant problems with increased rates of 
chromosome mutation. In this study, all of the chromosome 
examinations were normal. However, this finding does not com-
pletely eliminate the possibility of chromosome mutation in the 
hMSCs culture. The presence of chromosome mutation in im-
mortalized hMSCs, which were developed to sustain the char-
acteristics of hMSCs for long periods of time, have been report-
ed (21, 22). Therefore, careful observation of chromosomal 
anomalies of the hMSCs from the preterm placenta of embry-
onic and early fetal stages of development, which can prolifer-
ate longer than in the late fetal and adult stages, is needed. 
  There was a lower infection risk, especially for Mycoplasma 
spp., in the human bone marrow samples than in the human 
placentas. This finding might be due to the difference in the pro-
cedures used for tissue acquisition. Human bone marrow is ac-
quired using aseptic techniques in the operating room because 
the harvested bone marrow blood must be infused into patients. 
However, the handling of human placentas is somewhat crude 
because they are usually discarded after delivery. Therefore, 
human placentas must be more aseptically acquired to avoid 
microbiological contamination if hMSC cultures are to be de-
rived from placentas. So, in fact human placentas acquired from 
caesarean section delievery might be more useful than vaginal 
birth. 
  In summary, hMSCs from first trimester preterm hPCs in the 
embryo and early fetal stage show higher proliferation potential 
with the expression of pluripotency markers and telomerase 
activity than term hPCs during the late fetal stage and in adult 
hBM. These findings might be due to the fact that early gesta-
tional placentas are closer to the embryo stage than the late full 
term placentas. The hMSCs from term placentas might be use-
ful candidates for a source of hMSCs for the production of me-
sodermal cells without risk to donors. The results of this study 
demonstrate that hMSCs from the placenta have different char-
acteristics according to developmental stage. 
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